Document is current

Article History

Received: 12 December 2024

Revised: 13 February 2025

Accepted: 13 February 2025

First Online: 26 February 2025

Declarations

:

: Y.N. received consulting fees from Astellas Pharma and Daiichi-Sankyo, and lecture fees from AbbVie, Astellas, Chugai Pharmaceutical, Daiichi Sankyo, JCR Pharma, MSD, Novartis Pharma, Sumitomo Pharma, Amgen, Bristol-Myers Squibb, CSL Behring, Janssen Pharmaceutical, Kyowa Kirin, Nippon Shinyaku, Otsuka Pharmaceutical, Takeda Pharmaceutical, and Meiji Seika Pharma. H.H. received lecture fees from Bristol-Myers Squibb and advisory fees from Novartis Pharma. N.D. received grants from Japan Agency for Medical Research and Development (24ek0510039h0003) and Japan Society for the Promotion of Science (23K06709), consulting fees from Janssen Pharmaceutical, and lecture fees from Nippon Shinyaku, Novartis Pharma, Daiichi-Sankyo, AstraZeneca, Otsuka Pharmaceutical, Asahi Kasei Pharma, Sanofi, Pfizer, Janssen Pharmaceutical, Kyowa Kirin, AbbVie, Astellas Pharma, Chugai Pharmaceutical, Shionogi & Co, Merck & Co, and Takeda Pharmaceutical. None of these are related to the current study. Other authors declare no competing interests.

: This study was performed in accordance with the Declaration of Helsinki and approved by the ethics committee of Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital (approval number 2203). Written informed consent was obtained from the patients.